ABL Bio (KOSDAQ 298380) 2026 stock analysis: the Grabody-B blood-brain-barrier shuttle platform, the Sanofi Parkinson's licensing deal, 4-1BB bispecific immuno-oncology, ADC pipeline, milestone-and-royalty revenue, and the clinical and cash-burn risks.
Daejoo Electronic Materials (KOSDAQ 078600) 2026 stock analysis: silicon anode (Si anode) technology moat, conductive paste cash cow (MLCC and solar), LG Energy Solution value-chain exposure, and the EV-demand, commercialization-pace, and valuation risks investors must weigh.
Eugene Technology (KOSDAQ 084370) stock outlook for 2026. A deep, qualitative look at its LPCVD and ALD semiconductor deposition equipment moat, Samsung, SK hynix and Micron customer base, HBM and DDR5 capex leverage, plus memory-cycle volatility and customer-concentration risk.
InBody (KOSDAQ 041830) 2026 stock analysis for global investors: the world's leading body composition analyzer brand, B2B install base at hospitals and gyms, consumables and subscription recurring revenue, high overseas sales, net-cash balance sheet, and the FX, growth, and new-business risks.
Komico (KOSDAQ 183300) 2026 stock analysis: the leading semiconductor parts precision-cleaning and coating outsourcer, its fab-utilization-linked recurring revenue model, Samsung, SK hynix and Micron customer base, US, Taiwan and China expansion, AI and HBM leverage, and the memory-cycle risk.
Nano-Materials (KOSDAQ 121600) 2026 stock analysis: CNT conductive additive leverage as silicon anodes scale, the CMP slurry and TCO target businesses, EV-chasm and customer-concentration risks, valuation, and how foreign investors can access this Korean battery-materials name.